37859-24-8

Basic information

• Product Name: 4-Bromophenylacetyl chloride
• Synonyms: 4-BROMOPHENYLACETIC ACID CHLORIDE;(4-BROMO-PHENYL)-ACETYL CHLORIDE;2-(4-bromophenyl)ethanoyl chloride;(4-Bromo-phenyl)-acetyl chloride ,95%;Benzeneacetyl chloride,4-bromo-
• CAS NO: 37859-24-8
• Molecular Formula: C₈H₆BrClO
• Molecular Weight: 233.49
• Product Categories: pharmacetical
• Mol File: 37859-24-8.mol
• Article Data: 104

Chemical Properties

• Boiling Point: 180-185°C/10mm
• Flash Point: >110℃
• Appearance: /
• Density: 1.573 g/mL at 25 °C
• Vapor Pressure: 0.00296mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Bromophenylacetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromophenylacetyl chloride(37859-24-8)
• EPA Substance Registry System: 4-Bromophenylacetyl chloride(37859-24-8)

Safety Data

• Hazard Codes: C
• Statements: 34-22
• Safety Statements: 26-36/37/39-45
• RIDADR: 3265
• WGK Germany: 3
• Hazardous Substances Data: 37859-24-8(Hazardous Substances Data)

Usage

General Description

4-Bromophenylacetyl chloride is a chemical compound with the molecular formula C8H7BrO2. It is a white to light yellow solid that is soluble in organic solvents and reacts violently with water. It is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. 4-Bromophenylacetyl chloride is a versatile reagent in organic synthesis due to its ability to introduce the 4-bromophenylacetyl group into various molecules. It is also a useful building block in the development of new drugs and other bioactive compounds. However, it can be hazardous and should be handled with caution due to its potential to cause irritation to the skin, eyes, and respiratory tract.

InChI:InChI=1/C8H6BrClO/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4H,5H2

Upstream product

• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 7719-09-7 thionyl chloride 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1197-55-3 4-aminophenylacetic acid 

Downstream Products

• 67205-73-6 2-(4-bromophenyl)-1-(4-methoxyphenyl)-1-ethanone 
• 181364-80-7 2-(4-bromophenyl)-N,N-diethylacetamide 
• 22421-88-1 4-bromobenzyl phenyl ketone 
• 177846-87-6 ethyl 2-(4-bromophenylacetyl)-3-oxo-4-phenylbutanoate 
• 177846-26-3 methyl 2-(4-bromophenylacetyl)-3-oxobutanoate 
• 177846-59-2 ethyl 2-(4-bromophenylacetyl)-3-oxohexanoate 
• 349430-63-3 N-[(4-bromo-phenyl)-acetyl]-glycine ethyl ester 
• 294895-73-1 4-butylsulfanyl-α-(4'-bromophenyl)acetophenone 
• 62856-24-0 4-pentyl-α-(4'-bromophenyl)acetophenone 
• 6908-52-7 2-(4'-methyl-[1,1'-biphenyl]-4-yl)acetic acid 
• 302925-89-9 phenyl-acetic acid 4-{dimethyl-[3-(tris-{3-[dimethyl-(4-phenylacetoxymethyl-phenyl)-silanyl]-propyl}-silanyl)-propyl]-silanyl}-benzyl ester 
• 109558-15-8 2-(4-bromophenyl)-N-(3,4-dimethoxyphenethyl)acetamide 
• 592529-19-6 2-(4-bromo-phenyl)-1-{2-[2-(4-methylsulfanyl-phenyl)-2-oxo-ethyl]-pyrrolidin-1-yl}-ethanone 
• 252562-93-9 2-(4-bromophenyl)-1-(4-methylsulfanylphenyl)ethanone 

Relevant articles and documents

A novel complexity-to-diversity strategy for the diversity-oriented synthesis of structurally diverse and complex macrocycles from quinine

Recent years have witnessed a global decline in the productivity and advancement of the pharmaceutical industry. A major contributing factor to this is the downturn in drug discovery successes. This can be attributed to the lack of structural (particularly scaffold) diversity and structural complexity exhibited by current small molecule screening collections. Macrocycles have been shown to exhibit a diverse range of biological properties, with over 100 natural product-derived examples currently marketed as FDA-approved drugs. Despite this, synthetic macrocycles are widely considered to be a poorly explored structural class within drug discovery, which can be attributed to their synthetic intractability. Herein we describe a novel complexity-to-diversity strategy for the diversity-oriented synthesis of novel, structurally complex and diverse macrocyclic scaffolds from natural product starting materials. This approach exploits the inherent structural (including functional) and stereochemical complexity of natural products in order to rapidly generate diversity and complexity. Readily-accessible natural product-derived intermediates serve as structural templates which can be divergently functionalized with different building blocks to generate a diverse range of acyclic precursors. Subsequent macrocyclisation then furnishes compounds that are each based around a distinct molecular scaffold. Thus, high levels of library scaffold diversity can be rapidly achieved. In this proof-of-concept study, the natural product quinine was used as the foundation for library synthesis, and six novel structurally diverse, highly complex and functionalized macrocycles were generated.

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

The organocatalytic enantiodivergent fluorination of β-ketodiaryl-phosphine oxides for the construction of carbon-fluorine quaternary stereocenters

Commercially available cinchona alkaloids that can catalyze the enantiodivergent fluorination of β-ketodiarylphosphine oxides were developed to construct carbon-fluorine quaternary stereocenters. This protocol features a wide scope of substrates and excellent enantioselectivities, and it is scalable.